对SLC33A1的药理抑制促进了内分泌网膜过氧化,并诱导了自适应IRE1/XBP1s信号传输
bioRxiv : the preprint server for biology
|February 27, 2026
概括
小分子IXA4抑制ER传递器SLC33A1,影响ER氧化还原稳态. 这一发现为肺癌等疾病提供了新的治疗策略,通过准SLC33A1.1.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 细胞生物学 细胞生物学
背景情况:
- 细胞内膜网膜 (ER) 载体SLC33A1是各种疾病的潜在治疗点.
- 目前,SLC33A1没有特定的药理学调节剂.
研究的目的:
- 为了识别和描述SLC33A1.1.的药理学调节剂.
- 为了研究SLC33A1在细胞信号传递和恒温的作用.
- 为了探索SLC33A1抑制的治疗潜力.
主要方法:
- 小分子选和表征 (IXA4).
- 基因操纵 (SLC33A1的消耗).
- 化学蛋白质组分析和冷电子显微镜.
- 细胞活力测试. 细胞活力测试.
主要成果:
- IXA4可以选择性地结合并抑制SLC33A1的活性.
- 抑制SLC33A1导致ER光层过氧化和激活IRE1/XBP1s信号传递.
- 在KEAP1缺乏的肺腺癌细胞中,IXA4治疗选择性地降低了活力.
- 遗传 SLC33A1 枯竭 副本 IXA4 效应.
结论:
- SLC33A1在调节ER redox恒温中发挥着至关重要的作用.
- IXA4是一种新型的SLC33A1.1.的药理抑制剂.
- 用IXA4准SLC33A1为特定癌症和其他疾病提供了潜在的治疗途径.
相关概念视频
Regulation of the Unfolded Protein Response
3.1K
Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...
3.1K
The Unfolded Protein Response
6.6K
The ER is the hub of protein synthesis in a cell. It has robust systems to quality control protein folding and also for degradation of terminally misfolded proteins. Under normal conditions, a small proportion of misfolded proteins that cannot be salvaged need to be transported to the cytoplasm by the ER-associated degradation or ERAD pathways. However, if the ERAD cannot handle the misfolded proteins, the cell activates the unfolded protein response or UPR to adjust the protein folding...
6.6K
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
77
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
77
Export of Misfolded Proteins out of the ER
5.4K
After folding, the ER assesses the quality of secretory and membrane proteins. The correctly folded proteins are cleared by the calnexin cycle for transport to their final destination, while misfolded proteins are held back in the ER lumen. The ER chaperones attempt to unfold and refold the misfolded proteins but sometimes fail to achieve the correct native conformation. Such terminally misfolded proteins are then exported to the cytosol by ER-associated degradation or ERAD pathway for...
5.4K
ER Retrieval Pathway
4.9K
In the secretory pathway, vesicles transport proteins from one cellular compartment to another in forward transport to deliver the protein to its correct location. Occasionally, misfolded proteins and incorrect proteins escape their original compartments, and a retrieval pathway is used to return the escaped proteins to their original compartment.
The ER uses many checkpoints to prevent the entry of incorrectly folded or a resident protein as cargo onto a transport vesicle. These mechanisms...
The ER uses many checkpoints to prevent the entry of incorrectly folded or a resident protein as cargo onto a transport vesicle. These mechanisms...
4.9K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
54
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
54

